• Johnson & Johnson announced Phase 3 PROTEUS substudy results showing perioperative Erleada with hormone therapy reduced recurrence or death versus surgery alone.
• The regimen also delayed subsequent treatment and showed a numerical improvement in survival without metastasis in high-risk localized or locally advanced prostate cancer.
• Results were presented at the European Society for Medical Oncology Congress 2026, building on primary findings presented at ASCO 2026.
• Severe adverse events were more frequent with the regimen, which remains unapproved for this use; overall survival follow-up continues.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610240854PR_NEWS_USPR_____NY80016) on October 24, 2026, and is solely responsible for the information contained therein.